Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B.
- DOI
- 10.3390/ijms27209049
- Published
- 2026 Oct 12
- Container
- International journal of molecular sciences
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/ijms27209049,
title = {Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B.},
author = {Herbst K and Pezeshkpoor B and Klein C and Albert T and Lutz P and Strassburg C and Spengler U and Goldmann G and Oldenburg J},
year = {2026},
journal = {International journal of molecular sciences},
doi = {10.3390/ijms27209049},
url = {https://doi.org/10.3390/ijms27209049}
}RIS
TY - JOUR TI - Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B. AU - Herbst K AU - Pezeshkpoor B AU - Klein C AU - Albert T AU - Lutz P AU - Strassburg C AU - Spengler U AU - Goldmann G AU - Oldenburg J PY - 2026 JO - International journal of molecular sciences DO - 10.3390/ijms27209049 UR - https://doi.org/10.3390/ijms27209049 ER -
APA
K, H., B, P., C, K., T, A., P, L., C, S., U, S., G, G., & J, O. (2026). Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B.. International journal of molecular sciences. https://doi.org/10.3390/ijms27209049
Source records
- pubmed · retrieved 2026-11-10T18:10:36.562Z